Initially, the companies will collaborate to design a high-profile pilot study to marry traditional clinical operations with external data assets. The intent is to explore opportunities to enhance trial monitoring through focusing on patient compliance, adherence and overall enrollment feasibility.
Worldwide brings a deep appreciation of the pathophysiological mechanisms, innovative clinical trial designs, and operations rigor needed to move neurodegenerative disease research forward.
Datavant brings an ability to link traditional real-world medical data from electronic health records (EHRs), claims, genomics and diagnostics with emerging non-traditional sources, such as socioeconomic data, wearables/devices, and behavioural data.
Its software facilitates the creation of a holistic view of anonymous datasets, combining multiple data layers into a single de-identified dataset to help answer questions that were previously infeasible to address.
Worldwide Clinical Trials employs more than 1,600 professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia, and Asia.
From early phase and bioanalytical sciences through late phase, post-approval, and real-world evidence it provides full-service drug development services.
The company executes predictable, successful studies across a range of therapeutic areas, including central nervous system, cardiovascular, metabolic, immune-mediated inflammatory disorders (IMID), oncology, and rare diseases.
CSL reveals top-line outcome from Phase three AEGIS-II trial of CSL112
AstraZeneca invests USD300m to expand US manufacturing for cell therapy
Innovent Biologics announces CFO transition
Cardio Diagnostics appoints Dr Vimal Ramjee as Strategic Advisor
Acticor Biotech reports positive ACTIMIS clinical study results in Lancet Neurology Journal
Sarepta Therapeutics commences Phase 3 clinical study of SRP-9003 for LGMD2E